Infections in Patients with Cystic Fibrosis Diagnostic Microbiology Update
Infections in Patients with Cystic Fibrosis Diagnostic Microbiology Update
复制标题
DOI：
10.1016/j.cll.2014.02.001
复制
发表时间：
2014-06-01
影响因子：
1.7
通讯作者：
Gilligan, Peter H.
中科院分区：
文献类型：
--
作者：
Gilligan, Peter H.
囊性纤维化（CF）患者的生存率有所提高，部分原因是积极的抗菌药物管理。两种多重耐药环境细菌，洋葱伯克霍尔德菌群和非结核分枝杆菌，已经出现。基因组学和蛋白质组学技术的进步使我们能够更好地识别CF肺中发现的细菌和真菌，并检测可能与肺恶化相关的病毒因子。厌氧菌和血管链球菌群生物可能在慢性CF肺部感染中起作用。生物多样性下降可能是由于积极的抗微生物治疗的结果，顶端捕食者，铜绿假单胞菌，可能出现在许多CF患者。
Survival has improved in patients with cystic fibrosis (CF), in part because of aggressive antimicrobial management. Two multidrug-resistant environmental bacteria, the Burkholderia cepacia group and nontuberculous mycobacteria, have emerged. Improving genomic and proteomic technologies are allowing better identification of bacteria and fungi found in the CF lung and detection of viral agents that may be associated with pulmonary exacerbations. Anaerobic bacteria and Streptococcus angionsus group organisms may play a role in chronic CF lung infections. The diversity of organisms declines perhaps as a result of aggressive antimicrobial therapy, and an apex predator, Pseudomonas aeruginosa, may emerge in many patients with CF.